FDA Approves Priovant’s LISRAYA (Brepocitinib), the First Targeted Therapy for Dermatomyositis

Revolution Medicines set Rasonque at $39,800 a month, more than double Keytruda, while Europe’s larger nations dug in against U.S. most-favored-nation pressure and Washington lined up another round of voluntary deals.

Today’s top developments:

• The FDA approved Priovant’s LISRAYA (brepocitinib), a first-in-class TYK2/JAK1 inhibitor, as the first and only targeted therapy for adults with dermatomyositis — carrying a JAK-class boxed warning and backed by the Phase 3 VALOR trial, in which 55% of patients reached moderate-or-better improvement versus 30% on placebo (STAT)
• Revolution Medicines priced Rasonque (daraxonrasib) at $39,800 a month — roughly $477,600 a year, more than twice Keytruda — as Evercore ISI raised its estimates to $2.4 billion in 2027 and a $20.8 billion peak across indications, calling it potentially one of the fastest oncology launches in history (BioPharma Dive)
• Europe’s larger drug markets resisted U.S. most-favored-nation pricing pressure while Washington prepared a further round of voluntary MFN agreements — 17 drugmakers including Pfizer, Eli Lilly and Johnson & Johnson have already signed, with the administration projecting $529 billion in savings over a decade (Pharmaceutical Technology)
• AstraZeneca and Amgen’s Tezspire (tezepelumab) met both co-primary endpoints of the Phase 3 CROSSING trial in eosinophilic esophagitis — significant improvements in histologic remission and dysphagia at week 24, sustained to week 52 — though effect sizes were not disclosed (Pharmaphorum)
• The FDA granted De Novo authorisation to Vitestro’s Aletta, an autonomous blood-draw robot that posted a 94.5% first-stick success rate across 1,633 patients, with one trained supervisor able to oversee up to three devices (Forbes)